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Background/aim: Patients with inflammatory rheumatic diseases faced several challenges during the COVID-19 pandemic.
Uncertainties such as the lack of evidence regarding the use of immunosuppressive (IS) therapies and deferred patient care because of
limited health resources affected negatively on many aspects of treatment decisions and routine follow-up of the patients. In this study,
we aimed to investigate the prevalence and severity of SARS-CoV-2 infection, the impact of the pandemic on delays in routine clinical
follow-up, changes in IS treatment, and COVID-19 vaccination status of patients with Takayasu arteritis (TAK).
Materials and methods: The study was performed between July and September 2021. TAK patients who registered in our database
were investigated with regards to the COVID-19 infection and vaccination status, delays in routine clinical visits, changes in their IS
treatments, and flares during the pandemic. Physical examination, laboratory tests, and imaging of the patients were performed and
ITAS2010 scores were calculated.
Results: There were 56 adult TAK patients (87.5% female and median age 47 years). A total of 44 (78.6%) patients experienced a delay
with routine follow-up visits to their physicians and about 20% of patients stopped their antirheumatic treatments without consulting
their physicians. Compared to the pre-COVID-19 pandemic, 16 (28.5%) patients flared. In total group, 13 (23.2%) patients had a mild
COVID-19 infection and about 90% of the patients had received the COVID-19 vaccine.
Conclusion: Deferred patient care and disease flares are the most significant problems in TAK patients during the pandemic. The risk
of TAK flares may outweigh the risk of COVID-19 infection.
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1. Introduction
Coronavirus disease 2019 (COVID-19) is a significant
health problem with increased mortality and morbidity,
particularly for patients with underlying chronic disease
[1]. In this respect, patients with inflammatory rheumatic
diseases are considered at risk for a severe COVID-19
because of the abnormal immune response and the potential
use of the immunosuppressive (IS) therapies [2,3]. Takayasu
arteritis (TAK) is a rare form of large-vessel vasculitis mainly
affecting young women of Asian ethnicity. Vasculitis causing
narrowing, occlusion, or dilation of arteries may affect several
organ systems and may lead to numerous symptoms. Systemic
IS therapy is required to control disease activity and to prevent
complications [4]. The prevalence and impact of COVID-19
on patients with TAK are currently limited [5,6]. Herein,
due to the limited number of reports on COVID-19 and
TAK, we studied the prevalence and severity of SARS-CoV-2
infection, the impact of the pandemic on delays in routine
clinical follow-up, changes in IS treatment, and COVID-19
vaccination status of patients with Takayasu arteritis (TAK).

2. Materials and methods
TAK patients classifying the American College of
Rheumatology 1990 Takayasu arteritis were included in
the study [7]. Patients who provided informed consent
were asked the following questions during their routine
visits: (1) Have you been diagnosed with COVID-19? (2)
Have you regularly been taking your TAK medications?
(3) Have you experienced a relapse of your disease? (4)
Did you have a delay with routine follow-up visits to your
physician? (5) If the answer yes for question number five,
how long was it delayed? (6) Have you been vaccinated
for COVID-19? and (7) Have you experienced any side
effects related to the COVID-19 vaccine? Following the
inquiry, the patients were examined by a rheumatologist
and disease activity scores ITAS 2010 [8] and Kerr [9] were
calculated.
Demographic data, disease characteristics, duration of
diagnosis, comorbidities and treatments were recorded.
Severe COVID-19 infection was defined if the patient had
one of the following: hospitalization with a diagnosis of
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acute respiratory failure, need for noninvasive ventilation,
admission to an intensive care unit, or death [10]. The
study was performed between July and September 2021.
Ethical approval was obtained from the ethics committee
of Dokuz Eylül University School of Medicine and the
Ministry of Health, General Directorate of Health Services.
2.1. Statistical analysis
Normality was tested by using the Kolmogorov–Smirnov
test. Continuous variables were presented as median with
interquartile range (IQR). The chi-square test or Fisher’s
exact test was used to compare for categorical variables and
the Mann–Whitney U test was used for the comparison of
the continuous data. For all statistical analyses, a double
tailed p-value <0.05 was considered statistically significant.
Statistical analysis was carried out by using SPSS v.24.
3. Results
Out of 69 adult TAK patients who were registered in our
database, 56 (81.2%) were agreed to participate in the
study. Five patients died before the pandemic, 8 patients
refused to participate in the study (there was no mortality
in this group and the clinic data of these patients were not
shared). The median (Q1–Q3) age of the study patients
was 47 (37–60) years, 49 (87.5%) were female and the
median (Q1–Q3) disease duration was nine (4–17) years.
The general characteristics of the patients were given in
Table 1. There were 44 (78.6%) patients who experienced a
delay with their routine follow-up visits and about 20% of
the patients stopped their treatments without consulting
their physicians. The vast majority of the patients (n = 32,
73%) delayed their visits as they had difficulty getting an
appointment during the pandemic. The remainder (n =
12) of the patients did not attend their visits as a concern
for contacting the COVID-19 patients. Five (45.5%) out
of 11 patients experienced flare after three (2–6) months
of stopping their treatments. Compared to the preCOVID-19 pandemic (before 11.03.2020 when the first
COVID-19 case was seen in Turkey), 16 (28.5%) patients
flared according to Kerr criteria [9]. Fifty (91%) out of 56
patients were vaccinated for COVID-19. Patients who did
not get vaccinated mostly did not have their vaccines as of
concern with regards to the side effects of the vaccination
(n = 5). Only one patient rejected the vaccine on religious
grounds. The detailed data about the disease and
COVID-19 vaccination status were summarized in Table
2. Pain at the injection site, fatigue, and headache were the
most common side effects of the vaccination. There were
no serious adverse events related to the vaccination. A
total of 13 (23.2%) patients had a documented COVID-19
infection. All but one patient had both positive PCR tests

for COVID-19 and clinical symptoms. Although PCR
was negative in one patient, the diagnosis was made with
a history of close contact with a COVID-19 patient and
clinical symptoms. Eight of them had an infection before
the vaccination program started. Three of the patients had
an infection after a double dose of Sinovac-CoronaVac
COVID-19 vaccine, one after a single dose of SinovacCoronaVac COVID-19 vaccine, and the other after a
double dose of Pfizer-BioNTech COVID-19 vaccine.
Pneumonia was reported in five patients, and two of them
required hospitalization. One patient required intensive
care support. Three patients had a loss of taste and smell.
All patients were given Favipiravir and anticoagulant
based on local treatment guidelines1 for COVID-19,
and their DMARDs were stopped temporarily until two
weeks of symptom-free observation. None of the patients
required anticytokine therapy but one patient received oral
steroids for COVID-19 infection. All patients recovered
completely. There was also no mortality in the group of
patients who did not participate in the study. Comparison
of patients who had COVID-19 vs. without revealed that
patients infected with COVID-19 were younger and had
fewer comorbid diseases. The comparison of patients with
and without COVID-19 was given in Table 3.
4. Discussion
In this study, we revealed the following: about one fifth of
the TAK patients were infected with the COVID-19, the
course of infection was mild in about 95% of the patients
and there was no mortality because of COVID-19. The
majority of the TAK patients (about 90%) were agreed to
vaccinate against COVID-19. During the pandemic about
one third of the TAK patients flared and the majority of
these were observed in patients whose routine follow-ups
were delayed as healthcare resources largely utilized for
pandemic control.
IS treatments form the mainstay in controlling
disease activity in inflammatory rheumatic diseases
(IRDs). However, these medications are also of particular
concern for susceptibility to infections. Currently the
evidence regarding the use of IS therapies and their
impact of COVID-19 infection is limited. An Italian
study reported that 2 (3%) out of 67 TAK patients had a
confirmed diagnosis of COVID-19 and these patients did
not require hospitalization. Therefore authors speculated
that the use of IS therapy did not adversely affect the
course of COVID-19 [6]. In contrast, another study in
patients with large vessel vasculitis (LVV) documented
a higher hospitalization and mortality rates suggesting a
severe outcome in COVID-19 disease. They reported the

Footnote: Republic of Turkey Ministry of Health General Directorate of Public Health (2021), COVID-19 (SARS-CoV-2 Infection) adult patient treatment guideline: Turkey [online]. Website:https://covid19.saglik.gov.tr/Eklenti/42169/0/covid19rehberieriskinhastayonetimivetedavi20122021v6pdf.pdf
[accessed 12 Month 2021].
1
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Table 1. Clinical and demographic features of patients with Takayasu arteritis.
Demographic features

n = 56

Age, years, (median, Q1–Q3)

47 (37–60)

Female, n (%)

49 (87.5)

Disease duration, years (median, Q1–Q3)

9 (4–17)

Comorbid disease, n (%)

27 (48.2)

Hypertension

22 (39.3)

Coronary artery disease

6 (10.7)

Pulmonary arterial hypertension

2 (3.6)

Cerebrovascular accident

3 (5.4)

Diabetes mellitus

2 (3.6)

Chronic kidney disease

3 (5.4)

Other diseases

7 (12.5)

Current and ex-smoker

19 (37.3)

Artery involvement type[4] n(%)
Type 1

16 (28.6)

Type 2a

6 (10.7)

Type 2b

5 (8.9)

Type 3

2 (3.6)

Type 4

2 (3.6)

Type 5

25 (44.6)

CRP (mg/L) at last visit, (median, IQR, Q1–Q3)

4.5 (1.8–9.6)

ESR (mm/h) at last visit, (median, IQR, Q1–Q3)

19 (7–29)

Current treatments n (%)
Prednisolone n (%), median, Q1–Q3 dose (mg)

33 (58.9), 3 (0–4) mg

Methotrexate

19 (33.9)

Leflunomide

5 (8.9)

Mycophenolate mofetil

10 (17.9)

Azathioprine

13 (23.2)

Cyclophosphamide

1 (1.8)

Tocilizumab

5 (8.9)

Infliximab

6 (10.7)

cs-/bDMARD combination

10 (17.8)

Continuous data is presented with median (interquartile range, Q1–Q3) values
and categorical data are presented as counts (n) and percentages (%), csDMARD,
conventional synthetic disease-modifying antirheumatic drug; bDMARD,
biological disease-modifying antirheumatic drug; CRP; C-reactive protein; ESR;
erythrocyte sedimentation rate.

incidence of COVID-19 amongst the TAK cohort was
6.3%, and the mortality rate was 1.7% [11]. In another
study, among the vasculitis, TAK reported to be the group
with the lowest incidence of COVID-19 infection (2.4%,
n: 16/662) [12]. In our cohort, the rate of COVID-19 was
23.2% and only about 5% had severe COVID-19 without

any mortality. The higher frequency in our series could be
explained by the longer pandemic duration compared to
other studies. Current evidence suggested that the use of
disease modifying antirheumatic drugs (DMARDs) and
lower doses of prednisone (<10 mg/daily) did not increase
the severity of COVID-19 infection [3,13–15]. However,
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Table 2. Effects of COVID-19 pandemic on patients with Takayasu arteritis.
Patients with a delay regarding to the routine follow-up visits, n (%)

44 (78.6)

Average delay in routine follow-up visits since the beginning of COVID-19 pandemic (months), median, Q1–Q3

3.5 (2.25–9)

Patients who do not receive their treatment regularly due to COVID-19 concern

11 (19.6)

Disease relapse compared to the prepandemic time, n (%)

16 (28.6)

Progression in acute phase reactants, n (%)

14 (25)

Progression in vascular involvement (according to MR angiography or Doppler ultrasound findings) n (%)

15 (26.8)

Patients diagnosed with COVID-19 disease, n (%), prevaccination / postvaccination

13 (23.2), 8/5

Vaccination status, n (%)

50 (90.9)

Sinovac-CoronaVac COVID-19 vaccine single dose

2 (4)

Sinovac-CoronaVac COVID-19 vaccine double dose

9 (18)

Sinovac-CoronaVac COVID-19 vaccine triple dose

6 (12)

Pfizer-BioNTech COVID-19 Vaccine single dose

1 (2)

Pfizer-BioNTech COVID-19 Vaccine double dose

14 (28)

Sinovac-CoronaVac COVID-19 vaccine double dose + Pfizer-BioNTech COVID-19 Vaccine single dose

17 (34)

Sinovac-CoronaVac COVID-19 vaccine double dose + Pfizer-BioNTech COVID-19 Vaccine double dose

1 (2)

Continuous data is presented with median (interquartile range, Q1–Q3) values and categorical data are presented as counts (n) and
percentages (%).
Table 3. Comparison of patients diagnosed with and without COVID-19 disease.

Variables

COVID-19 (+)
patients
n = 13

COVID-19 (-)
patients
n = 43

p value

Age, mean ± SD

39.7 ± 10.5

48.7 ± 14.4

0.042

Female, n (%)

11 (84.6)

38 (88.4)

0.720

Disease duration, years, median (IQR, Q1–Q3)

11 (5–12)

7 (3-18)

0.892

Disease duration, years, Mean ± SD

11.1 ± 9.5

9.3 ± 4.5

0.369

CRP (mg / L) at last visit, (median, IQR, Q1–Q3)

1.4 (0.8–7)

3.5 (1.1–7.6)

0.285

ESR (mm/h) at last visit, (median, IQR, Q1–Q3)

11 (4–19.5)

14.5 (7–25.3)

0.312

ITAS2010 score at last visit

2 (0–6)

3 (0-5)

0.911

Prednisolone

8 (61.5)

25 (58.1)

0.827

Methotrexate

2 (15.4)

17 (39.5)

0.107

Leflunomide

0 (0)

5 (11.6)

0.198

Mycophenolate mofetil

4 (30.8)

6 (14)

0.165

Azathioprine

4 (30.8)

9 (20.9)

0.462

Infliximab

3 (23.1)

3 (7)

0.130

Tocilizumab

3 (23.1)

2 (4.7)

0.076

Current and ex-smoker

4 (33.3)

15 (38.5)

0.748

Comorbidities, n (%)

3 (23.1)

24 (55.8)

0.038

Current treatments

n, number of patients; SD, standard deviation; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; DMARD,
disease-modifying antirheumatic drug.
Student’s t-test was used for the data conforming to normal distribution in the independent groups; the Mann–Whitney
U test was used for the data that do not conform to normal distribution. Fisher’s exact test and chi-square test was used
for categorical data, p < 0.05.
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higher doses of corticosteroids (CS) have been associated
with delayed viral clearance from the blood and respiratory
tract [16,17]. In our cohort 58.9 % of patients were on CS
and but only three patients were taking steroids over 10
mg/day.
Taken together with the low CS doses, younger
age and low comorbidities among COVID-19 patients
may contributed to the milder outcome for COVID-19
infection in our patients.
In many countries pandemic affected the health system
profoundly. Available healthcare resources including
outpatient care used to treat and control the COVID-19
infection. This affected the routine follow-ups of the
patients who have chronic diseases. In our cohort, nearly
80% of our patients reported that they experienced a delay
with their follow-up visits to their physicians. Both the
lack of communication between patients and physicians
and concern for COVID-19 infection in some patients
about 20% of the cohort stopped their medications. This
was resulted a disease flare in 45.5% of the patients who
discontinued their treatments. Similar to our study, nearly
70% of the vasculitis patients reported delays in their
follow-ups and about 10% needed to stop IS therapies [12].
Vaccination is the most effective form of protection
against COVID-19. In our country both inactive and
mRNA vaccines are present and about 60% of the
population has been vaccinated against COVID-19. The
vaccination rate among our TAK cohort is 91% and only
five patients refused the vaccine for various reasons. There
were no mortality in the total TAK cohort as because of
COVID-19. It is of concern that vaccination may have
an effect on disease flares. Based on self-reports, 5% of
patients with autoimmune disease reported deterioration

of their disease within two months of vaccination [18].
In our study, we evaluated our patients based on ITAS10
score and there was no deterioration of TAK activity after
the vaccination.
The main limitation of the current study was the small
sample size and therefore limited statistical power. We also
acknowledge that our population was derived from a single
center which may also be considered to be a limitation.
However, when considering the rarity of the TAK, current
data is providing important information to the researchers
as there was a substantial number of patients who were
being followed up in one of the largest TAK cohorts in the
country.
In summary, COVID-19 disease in TAK patients
were in mild severity and IS therapy seem not affecting
the COVID-19 course. A substantial number of patients
who stopped their medications flared and its long-term
consequences need to be assessed by large-scale studies.
New approaches are required to maximize healthcare
access for patients who have chronic diseases during
pandemic.
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